Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Andreas Hochhaus,G. Saglio,Timothy P. Hughes,Richard A. Larson,D. W. Kim,Surapol Issaragrisil,P. le Coutre,Gabriel Etienne,Pedro Enrique Dorlhiac-Llacer,Richard E. Clark,Ian W. Flinn,Hirohisa Nakamae,B. Donohue,Weiping Deng,Darshan Dalal,Hans D. Menssen,Hagop M. Kantarjian

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

2016

Andreas Hochhaus
G. Saglio
Timothy P. Hughes
Richard A. Larson
D. W. Kim
Surapol Issaragrisil
P. le Coutre
Gabriel Etienne
Pedro Enrique Dorlhiac-Llacer
Richard E. Clark
Ian W. Flinn
Hirohisa Nakamae
B. Donohue
Weiping Deng
Darshan Dalal
Hans D. Menssen
Hagop M. Kantarjian

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Keywords:

Nilotinib
Cancer research
Chronic phase chronic myeloid leukemia
Leukemia
Immunology
Hematology
Internal medicine
Myeloid leukemia
Oncology
Medicine
Imatinib
treatment outcome
follow up studies
imatinib mesylate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

463

Citations